PBRM1 and nonpapillary renal cell carcinoma: In both CheckMate and TCGA cohort, we observed enriched HRD-associated mutational signature 3 (P < 0.001 and P = 0.016 respectively; Fig. 1A, B) as well as RAD51 loss of expression (P = 0.076 and P = 0.037 respectively; Fig. 1A, B), a HR functional marker, in PBRM1-loss ccRCC.